Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Esophageal Neoplasms 9Colorectal Neoplasms 9Rectal Neoplasms 7Colonic Neoplasms 7Adenocarcinoma Of Esophagus 7Esophageal Squamous Cell Carcinoma 5Stomach Neoplasms 2Pancreatic Neoplasms 2Carcinoma, Hepatocellular 2Liver Neoplasms 1Gastrointestinal Neoplasms 1Gallbladder Neoplasms 1

Interventions

Gemcitabine 685130-nm albumin-bound paclitaxel 199Fluorouracil 190Oxaliplatin 177Albumin-Bound Paclitaxel 154Capecitabine 137Leucovorin 133Irinotecan 114Radiotherapy 96Taxes 85pembrolizumab 81Cisplatin 73Erlotinib Hydrochloride 70Radiosurgery 69Nivolumab 56Drug Therapy 56Bevacizumab 54Magnetic Resonance Spectroscopy 51Cyclophosphamide 50folfirinox 45Specimen Handling 43Docetaxel 42Cetuximab 40Biopsy 39irinotecan sucrosofate 38S 1 (combination) 36Pancreaticoduodenectomy 35Blood Specimen Collection 34Surgical Procedures, Operative 31Paclitaxel 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × Gefitinib × Gastrointestinal × Clear all
NCT00137761 2009-11-02

Docetaxel in Combination With Iressa in Previously Treated Patients With Pancreatic Cancer

Dana-Farber Cancer Institute

Phase 2 Completed
32 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT00234416 2009-04-23

IRESSA Combined With Radiotherapy & Gemcitabine as First-Line Treatment in Locally Advanced Pancreatic Cancer

AstraZeneca

Phase 1/2 Completed
45 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡